Skip to content

VoluitLeven.nl.

‘VoluitLeven.nl’. A randomized controlled trial on the effects of a online intervention based on Acceptance and Commitment Therapy for adults with mild to moderate mood symptoms and -disorders.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON22631
Enrollment
195
Registered
2011-07-28
Start date
2011-03-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mood symptoms and -disorders. Stemmingsklachten en - stoornissen.

Interventions

Sponsors

University of Twente
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Participants are adults of 18 years and older, with no apparent psychopathology. However, they have mild to moderate mood symptoms and -disorders.

Exclusion criteria

Exclusion criteria: 1. Serious psychopathology requiring immediate treatment measured with the M.I.N.I.-Plus and the SDS. When there is serious psychoptahology, the clients will be referred to contact their general practitioner for treatment; 2. The presence of a mild to high suicide risk, measured by the M.I.N.I.-Plus; 3. People recently started on pharmacological treatment (for the mood symptoms or - disorders), within three months (before the start of the research); 4. Currently undergoing psychological (self-help) treatment; 5. Not enough time for following the onlinetraining; 6. Inadequate control of the Dutch language (reading or learning difficulties).

Design outcomes

Primary

MeasureTime frame
Reduction of mood symptoms and disorders.

Secondary

MeasureTime frame
Reduction of symptoms of anxiety and an improvement of mindfulness, positive mental health, psychological flexibility, agency and mindfulness. Reduction in costs of diseaese and health care use.

Contacts

Public ContactWendy Pots

Postbus 217

w.t.m.pots@gw.utwente.nl+31 (0)53 489 3913

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)